文献速递贫血与红细胞疾病

氯沙坦治疗镰状细胞贫血肾病:一项2期多中心试验

Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
PubMed 文献 · Am J Hematol · 2017-07-19

这项2期多中心试验评估口服氯沙坦6个月对镰状细胞贫血患者白蛋白尿的影响,32例可评估参与者按基线尿白蛋白与肌酐比值(UACR)分为无白蛋白尿组、微量白蛋白尿组和大量白蛋白尿组。主要终点为UACR较基线降低≥25%,大量白蛋白尿组达标率83%(P<0.0001),微量白蛋白尿组58%(P<0.0001)。

要点

  • 大量白蛋白尿组主要终点达标率83%(P<0.0001),微量白蛋白尿组为58%(P<0.0001)。
  • 大量白蛋白尿组UACR中位倍数变化为-0.74,微量白蛋白尿组为-0.46。
  • 大量白蛋白尿组和微量白蛋白尿组中UACR分类改善者占50%,恶化者占11%。

核心结论

  • 氯沙坦降低了大多数伴白蛋白尿的参与者尿白蛋白排泄,其中大量白蛋白尿者获益最大。
  • 本研究为氯沙坦治疗镰状细胞贫血肾病的3期随机安慰剂对照试验奠定了基础。

研究设计与样本

  • 2期多中心试验,口服氯沙坦治疗6个月,探索其是否降低镰状细胞贫血儿童和成人的白蛋白尿。
  • 参与者按基线UACR类别分配至无白蛋白尿组(NoA)、微量白蛋白尿组(MicroA)和大量白蛋白尿组(MacroA)。
  • 共32例可评估参与者,平均年龄24岁;NoA=14例,MicroA=12例,MacroA=6例。
  • 主要终点为UACR较基线降低≥25%。

主要发现

  • 主要终点在MacroA组达标率83%(P<0.0001),在MicroA组达标率58%(P<0.0001)。
  • UACR中位倍数变化:MacroA组为-0.74,MicroA组为-0.46。
  • 在MacroA和MicroA组中,UACR分类改善者占50%,恶化者占11%。
  • 尿渗透压和估算肾小球滤过率(eGFR)无显著变化。
  • 白蛋白尿与舒张功能障碍和功能容量受损相关,但氯沙坦治疗6个月后心肺状态无变化。

关键数值与推荐

  • 主要终点达标率:MacroA组83%(P<0.0001),MicroA组58%(P<0.0001)。
  • UACR中位倍数变化:MacroA组-0.74,MicroA组-0.46。
  • UACR分类改善者占50%,恶化者占11%(MacroA和MicroA组)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 3例参与者停用氯沙坦:腿痉挛1例;eGFR下降>25%(142➝104 mL/minute/1.73 m2)1例;血清肌酐升高>50%(0.2➝0.3 mg/dL)1例。
  • 原文结论指出本研究为3期随机安慰剂对照试验奠定了基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nephropathy is a common and progressive complication of sickle cell anemia (SCA). In SCA mice, we found that hyperangiotensinemia in the absence of hypertension underlies nephropathy, and its downregulation by losartan, an angiotensin-II-receptor-1 blocker, reduced albuminuria and progression of nephropathy. Therefore, we performed a phase-2 trial of oral losartan, given for 6 months, to explore whether it reduced albuminuria in children and adults with SCA. Participants were allocated to groups defined by class of baseline urinary albumin-to-creatinine ratio (UACR): no albuminuria (NoA), microalbuminuria (MicroA), and macroalbuminuria (MacroA). The primary endpoint was a ≥25% reduction UACR from baseline. There were 32 evaluable participants (mean age 24 years; NoA = 14, MicroA = 12, MacroA = 6). The primary endpoint was met in 83% of the MacroA group (P < 0.0001) and 58% of the MicroA group (P < 0.0001). Median fold-change in UACR was -0.74 for MacroA and -0.46 for MicroA. In MacroA and MicroA, UACR classification improved in 50% but worsened in 11%. Urine osmolality and estimated glomerular filtration rate (eGFR) did not change significantly. Losartan was discontinued in three participants [leg cramps, N = 1; decline in eGFR >25% (142➝104 mL/minute/1.73 m2 ), N = 1; rise in serum creatinine >50% (0.2➝0.3 mg/dL), N = 1]. Albuminuria was associated with diastolic dysfunction and impaired functional capacity, although cardiopulmonary status was unchanged after 6 months of losartan therapy. In summary, losartan decreased urinary albumin excretion in most participants with albuminuria. Those with macroalbuminuria had the greatest benefit. This study forms the basis for a phase-3, randomized, placebo-controlled trial of losartan for the nephropathy of SCA.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Quinn CT, Saraf SL, Gordeuk VR, et al. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. Am J Hematol. 2017. PMID: 28589652. doi:10.1002/ajh.24810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。